摘要
沙格列汀与二甲双胍缓释片均对血糖水平起到调节作用,在降低患者血糖水平的基础上,能够起到规避低血糖风险的作用,调节效果较好。同时,上述药物联合使用,能够对患者的心脑血管系统产生强有力的保护效果,确保心脑血管的安全性。目前,有新技术实现二者联合制药,沙格列汀和二甲双胍复方药剂投入糖尿病治疗应用中,简化用药,能够避免患者对治疗产生懈怠心理,防止患者由于记忆力不佳而出现漏服、误服情况,患者治疗的依从性逐步提高,有益于控制糖尿病恶性进展。本文主要归纳、分析沙格列汀和二甲双胍缓释片治疗2型糖尿病研究进展。
Saxagliptin and metformin sustained-release tablets play a role in regulating blood glucose levels. On the basis of reducing blood glucose levels in patients, they can play a role in avoiding the risk of hypoglycemia and have a good regulation effect. At the same time, the combined use of the above drugs can produce a strong protective effect on the patient＇s cardiovascular and cerebrovascular system and ensure the safety of cardiovascular and cerebrovascular diseases. At present, there are new technologies to achieve the combination of the two drugs. Saxagliptin and metformin compound in the treatment of diabetes, with simplify administration, can avoid the patients＇ slackening of treatment, to prevent patients from missed drug and misuse due to poor memory. In the situation, the compliance of patients＇ treatment is gradually improved, which is beneficial to control the malignant progression of diabetes. This article summarizes and analyzes the research progress on saxagliptin and metformin sustained-release tablets in the treatment of type 2 diabetes.
作者
朱海夫
李思瓯
邓卫红
王彤彤
ZHU Haifu;LI Siou;DENG Weihong;WANG Tongtong(Department of Endocrinology,Hongqi Hospital Affiliated to Mudanjiang Medical College,Mudanjiang 157011,China;The First Clinical Medical College of Mudanjiang Medical College,Mudanjiang 157011,China)
出处
《中国现代医生》
2018年第28期165-168,共4页
China Modern Doctor
关键词
2型糖尿病
沙格列汀
二甲双胍缓释片
研究进展
Type 2 diabetes；Saxagliptin；Metformin sustained-release tablets；Research progress
作者简介
通讯作者:王彤彤
